<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2064" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="742" end="747"/>
    <type:ORR xmi:id="17" sofa="6" begin="920" end="925"/>
    <type:ORR xmi:id="21" sofa="6" begin="986" end="991"/>
    <type:PFSMean xmi:id="25" sofa="6" begin="1107" end="1117"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1265" end="1268"/>
    <type:PFSMean xmi:id="41" sofa="6" begin="1352" end="1355"/>
    <type:OSMean xmi:id="29" sofa="6" begin="1177" end="1187"/>
    <type:OSMean xmi:id="37" sofa="6" begin="1273" end="1283"/>
    <type:OSMean xmi:id="45" sofa="6" begin="1360" end="1370"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Vinflunine is a new microtubule inhibitor with preclinical activity&#13;&#10;in small cell lung cancer (SCLC). In this phase II trial, we evaluated vinflunine&#13;&#10;in patients with relapse-sensitive and refractory SCLC.&#13;&#10;METHODS: This trial aimed to achieve a 20% objective response rate (ORR) in&#13;&#10;platinum-sensitive patients. Patients with Eastern Cooperative Oncology Group&#13;&#10;performance status 0 to 2 and measurable disease received vinflunine (320 mg/m(2)&#13;&#10;IV) every 21 days (&lt; or =6 cycles; response evaluation every 6 weeks).&#13;&#10;RESULTS: Patient characteristics (N = 51): median age 63 years (range, 37-85&#13;&#10;years); male, 55%; Eastern Cooperative Oncology Group performance status 2, 16%; &#13;&#10;relapse-sensitive SCLC, 53%. The overall ORR was 19.6% (95% confidence interval&#13;&#10;[CI] 10-33%). Twelve (23.5%) patients had stable disease; 18 (35.3%) patients had&#13;&#10;progressive disease. Among relapse-sensitive patients, ORR was 22.2% (95% CI&#13;&#10;9-42%). Among relapse-refractory patients, ORR was 16.7% (95% CI 5-37%). Median&#13;&#10;follow-up was 15 months (range, 12-18 months); median progression-free survival&#13;&#10;(PFS) was 1.6 months (95% CI 1.3-3.9 months); median overall survival (OS) was&#13;&#10;4.9 months (95% CI 3.2- 6.5 months). Among relapse-sensitive patients, PFS and OS&#13;&#10;were 1.6 and 4.9 months, respectively. Among relapsed-refractory patients, PFS&#13;&#10;and OS were 1.4 and 4.0 months, respectively. In general, vinflunine was well&#13;&#10;tolerated, although neutropenia was a notable toxicity. Grade 3/4 toxicities&#13;&#10;(&gt;5%): neutropenia (32%), arthralgia/myalgia (16%), fatigue (16%), hyponatremia&#13;&#10;(12%), leukopenia (12%), nausea/vomiting (12%), constipation (6%), and&#13;&#10;thrombocytopenia (6%). The rates of toxicities were relatively well balanced&#13;&#10;among relapse-sensitive and refractory patients; one patient died of sepsis that &#13;&#10;was possibly treatment related.&#13;&#10;CONCLUSIONS: Vinflunine has activity in relapsed SCLC, including refractory&#13;&#10;relapsed patients. Neutropenia was common but associated with rare febrile&#13;&#10;episodes. Additional study in relapse-refractory SCLC is indicated."/>
    <cas:View sofa="6" members="1 13 17 21 25 33 41 29 37 45"/>
</xmi:XMI>
